<DOC>
	<DOC>NCT00732771</DOC>
	<brief_summary>The purpose of this study is to determine if LCI699, thorough reductions in aldosterone, can lower BP in patients with Primary hyperaldosteronism.</brief_summary>
	<brief_title>Proof-of-concept for the Aldosterone Synthase Inhibitor LCI699 in Patients With Primary Hyperaldosteronism</brief_title>
	<detailed_description />
	<mesh_term>Hyperaldosteronism</mesh_term>
	<criteria>Diagnosis of primary hyperaldosteronism (PH) within the last 3 years, either with or without an aldosterone producing adenoma (APA). Hypertension at screening Persistent hypokalemia Renal impairment Significant hepatic disease Any surgical or medical condition which may significantly alter the absorption, distribution, metabolism or excretion of any drug substance Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>primary hyperaldosteronism</keyword>
	<keyword>hypokalemia</keyword>
	<keyword>hypertension</keyword>
	<keyword>aldosterone synthase inhibitor</keyword>
</DOC>